A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease (HART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00724048
Recruitment Status : Completed
First Posted : July 29, 2008
Last Update Posted : July 22, 2016
Information provided by (Responsible Party):
Teva Pharmaceutical Industries

Brief Summary:
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.

Condition or disease Intervention/treatment Phase
Huntington Disease Drug: ACR16 10 mg Drug: ACR16 22.5 mg Drug: ACR16 45 mg Other: Placebo Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 227 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)
Study Start Date : October 2008
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ACR16 10 mg

Participants receive one ACR16 10mg twice daily:

First four weeks - ACR16 10mg qd - one active 10mg capsule daily. After four weeks - ACR16 10mg bid - two active 10mg capsules taken as two separate doses (20mg ACR16 per day).

Drug: ACR16 10 mg
ACR16 capsules: 10mg twice daily
Other Name: pridopidine

Experimental: ACR16 22.5 mg

Participants receive one ACR16 22.5mg capsule twice daily:

First four weeks - ACR16 22.5mg qd - one active 22.5mg capsule daily. After four weeks - ACR16 22.5mg bid - two active 22.5mg capsules taken as two separate doses (45mg ACR16 per day).

Drug: ACR16 22.5 mg
ACR16 capsules: 22.5mg twice daily

Experimental: ACR16 45 mg

Participants receive one ACR16 45mg capsule twice daily:

First four weeks - ACR16 45mg qd - one active 45mg capsule daily. After four weeks - ACR16 45mg bid - two active 45mg capsule taken as two separate doses (90mg ACR16 per day).

Drug: ACR16 45 mg
ACR16 capsules: 45mg twice daily

Placebo Comparator: Placebo

Weeks 1-4, Participants receive a one placebo capsule once daily for four weeks.

Weeks 5-26, Participants receive a one placebo capsule taken twice daily as two separate doses.

Other: Placebo
Placebo capsules

Primary Outcome Measures :
  1. Sum score of items 4-10 and 13-15 of the UHDRS motor assessment [ Time Frame: 26 Weeks ]
    The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score in MS) at 26 weeks of treatment.

Secondary Outcome Measures :
  1. Clinical Global Impressions (CGI) [ Time Frame: At 4, 8, 12 and 26 weeks ]
    The effects of ACR16 on CGI, cognitive function, behaviour and symptoms of depression and anxiety. CGI has two components—the CGI-Severity, which rates illness severity, and the CGI-Improvement, which rates change from the initiation (baseline) of treatment.

  2. Adverse event profile [ Time Frame: 30 weeks ]
    Safety and tolerability assessed from adverse event profile

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to provide written Informed Consent prior to any study related procedure, including consent to genotyping of the CYP2D6 gene.
  • Clinical features of HD, and a positive family history and/or the presence of ≥ 36 CAG repeats in the Huntington gene.
  • Male or female age ≥ 30 years.
  • Willing and able to take oral medication and to comply with the study specific procedures.
  • Ambulatory, being able to travel to the assessment center, and judged by the Investigator as likely to be able to continue to travel for the duration of the study.
  • Availability of a caregiver or family member to accompany the subject to two visits.
  • A sum of ≥ 10 points on the mMS at the screening visit.
  • For subjects taking allowed antidepressants or other psychotropic medication , the dosing of medication must have been kept constant for at least 6 weeks before enrollment.

Exclusion Criteria:

  • Treatment with any antipsychotic medication (neuroleptics) within 8 weeks of enrollment, or at any time point during the study period.
  • Use of tetrabenazine within 12 weeks of enrollment, or at any time during the study period.
  • Treatment with any investigational product within 4 weeks of enrollment.
  • Use of tricyclic antidepressants or class I antiarrhythmics within 6 weeks of enrollment, or at any time during the study period.
  • Use of concomitant medication that may lower the seizure threshold within 6 weeks of enrollment, or at any time during the study period .
  • Use of metoclopramide within 12 weeks of enrollment, or at any time during the study period.
  • Subjects currently receiving deep brain stimulation (DBS).
  • Subjects with a history of surgical procedures aiming to improve the symptoms of Huntington disease, such as neural transplantations, lesions of the central nervous system, infusions of neurotrophic agents or previous attempts of deep brain stimulation.
  • Subjects previously randomized into this study.
  • A prolonged QTc interval at Screening Visit (defined as a QTc interval of > 450 msec for males or > 470 msec for females), or other clinically significant heart conditions as judged by the investigator.
  • Creatinine clearance <40mL/min as measured at the screening visit.
  • Any clinically significant, abnormal, baseline laboratory result which in the opinion of the Investigator, affects the subjects' suitability for the study or puts the subject at risk if he/she enters the study.
  • Clinically significant hepatic or renal impairment.
  • Subjects with a known history of epilepsy or a history of febrile seizure(s) or seizure(s) of unknown cause.
  • Severe intercurrent illness, which, in the opinion of the Investigator, may put the subject at risk when participating in the trial or may influence the results of the trial or affect the subjects' ability to take part in the trial.
  • Alcohol and/or drug abuse as defined by DSM IV-TR criteria for Substance Abuse - this includes the illicit use of cannabis within the last 12 months prior to Screening Visit
  • Subjects with suicidal ideation as defined as a positive score on criteria for major depressive episode, item A9 on the DSM -IV-TR criteria for a Major Depressive Episode
  • Females who are pregnant or lactating or who intend to become pregnant during the study period.
  • Females who are of child bearing potential and not taking adequate contraceptive precautions are excluded from the trial. (Females of child bearing potential taking acceptable contraceptive precautions can be included)
  • Known allergy to any ingredients of the trial medication or placebo
  • Any previous participation in a clinical study with ACR16.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00724048

  Hide Study Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
United States, California
University of California
San Diego, California, United States, 92161
United States, Colorado
Colorado Neurological Institute
Littleton, Colorado, United States, 80120
United States, Florida
University of South Florida
Tampa, Florida, United States, 33612
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Indiana
Indiana University School of Medicine
Indianapolis, Indiana, United States, 46202
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Maryland
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201
Johns Hopkins University
Baltimore, Maryland, United States, 21287-7281
United States, Massachusetts
Massachusetts General Hospital
Charlestown, Massachusetts, United States, 02129
United States, Minnesota
Struthers Parkinson's Center
St. Louis Park, Minnesota, United States, 55426
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
Albany Medical College
Albany, New York, United States, 12208
North Shore-LIJ Health System
Manhasset, New York, United States, 11030
University of Rochester
Rochester, New York, United States, 14618
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45219
Ohio State University Parkinson's Center
Columbus, Ohio, United States, 43210
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19107
United States, Tennessee
University of Tennessee Health Science Center
Memphis, Tennessee, United States, 38163
United States, Texas
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390-9036
Baylor College of Medicine
Houston, Texas, United States, 77030
United States, Washington
Booth Gardner Parkinson's Care Center
Kirkland, Washington, United States, 98034
Canada, Alberta
University of Alberta Glenrose Rehab Hospital
Edmonton, Alberta, Canada, T5G 0B7
Canada, British Columbia
University of British Columbia
Vancouver, British Columbia, Canada, V6T 2B5
Canada, Ontario
London Health Sciences Centre
London, Ontario, Canada, N6A 5A5
The Centre for Addiction and Mental Health
Markham, Ontario, Canada, L6B1C9
Parkinsons and Neurodegenerative Disordes Clinic
Ottawa, Ontario, Canada, K1G4G3
Canada, Quebec
Hotel-Dieu Hospital-CHUM
Montreal, Quebec, Canada, H2L4M1
Sponsors and Collaborators
Teva Pharmaceutical Industries
Study Director: Joakim Tedroff, MD NeuroSearch A/S

Responsible Party: Teva Pharmaceutical Industries Identifier: NCT00724048     History of Changes
Other Study ID Numbers: ACR16 C009
First Posted: July 29, 2008    Key Record Dates
Last Update Posted: July 22, 2016
Last Verified: July 2016

Keywords provided by Teva Pharmaceutical Industries:
Huntington Disease

Additional relevant MeSH terms:
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Neurocognitive Disorders
Mental Disorders